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Adverse eventsAbstract Objectives: The aim of this study was to assess the safety and probability of adverse
events associated with the use of 75 mg pregabalin post hemodialysis (pHD) among patients with
UP. Methods: A cross-sectional study done among the hemodialysis patients suffering from uremic
pruritus (UP) Aljaber Kidney Center (AJKC), Al-Ahsa, Eastern Province, Saudi Arabia. Assess-
ment for the safety proﬁle of pregabalin was done using Naranjo’s algorithm. A predictive model
was developed using binary multiple logistic regression to explore association of patients’ demo-
graphics and risk factors with the occurrence of AEs. Throughout statistical signiﬁcance level
was considered signiﬁcant at 0.05. Key ﬁndings: Assessment of safety of pregabalin revealed that
somnolence and dizziness were the two frequent adverse events followed by constipation, weight
gain and edema. However, it was noticed that female patients aged less than 50 years were found
to be at a higher risk in comparison with men. Moreover, those patients having one comorbid com-
plication (i.e. hypertension or diabetes mellitus alone) were at a higher risk of somnolence, weight
gain and dry mouth. Conclusion: Naranjo’s quantiﬁcation for the possibility and probability of
adverse events reﬂect that all the events were probable. Age, gender and comorbid medical condi-
tions are some of the factors that might have clinical association with the occurrence of the AEs.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Uremia pruritus (UP) is one of the most common complica-
tions faced by patients with end stage renal disease (ESRD)
(Denman, 1986; Goicoechea et al., 1999; Greaves, 2005;
Hiroshige and Kuroiwa, 1996; Kfoury and Jurdi, 2012). Due
to complex pathophysiology of disease, variety of drugs such
as anti-histaminic, opioids agonist, emollients, antidepressants
and neuroleptic drugs are tested to provide relief to the ESRD
Safety of pregabalin among hemodialysis patients 615suffering through UP (Alomar et al., 2008; Anand, 2013;
Andersen et al., 1984; Aramwit et al., 2012; Balaskas et al.,
1998; Begum et al., 2004; Breneman et al., 1992; Cho
et al., 1997; De Marchi et al., 1992; Lin et al., 2012; Peck
et al., 1996; Schmitz et al., 2002). In most of the cases relief
from UP was short term and patients have suffered the conse-
quences in the form of relapse to UP. However, recent studies
that has tested pregabalin (PG), provided evidence of promis-
ing relief to the patients suffering from treatment resistant UP.
Shavit et al., (2013) have reported on the therapeutic effective-
ness of pregabalin 25–50 mg/day among UP patients showing
resistance to antihistamines and emollients (Shavit et al.,
2013). In addition other studies have also reported on the
effectiveness of pregabalin 25 mg/day among ESRD patients
with treatment resistance pruritus (previously tested for emol-
lients, antihistaminic and UV light) (Aperis et al., 2010;
Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al.,
2013; Solak et al., 2012).
Addressing the safety proﬁle of the pregabalin the drug
development data reﬂect the pregabalin safety among health
population and till to date there is limited safety data for pre-
gabalin among ESRD patients (Pregabalin, 2009). Recent case
studies and case series have reported some adverse events that
were found associated with the use of pregabalin among
patients with treatment resistant pruritus (Aperis et al., 2010;
Ehrchen and Stander, 2008; Rayner et al., 2012; Shavit et al.,
2013; Solak et al., 2012). However, the signiﬁcance and
probability of these events is not yet tested using any algorithm
that assist in quantifying the signiﬁcance/probability of these
events. Naranjo’s algorithm is widely used globally in order
to test the probability/signiﬁcance of a drug related event
(Khan et al., 2013; Naranjo et al., 1981; Smyth et al., 2012).
For a drug like pregabalin that is renally cleared, it is very
essential to estimate its safety proﬁle when it is considered to
be used among ESRD patients. Till to date there is a scarcity
of any evidence for the safety and efﬁcacy of pregabalin among
ESRD patient from Arab region. The current study will
address this issue using a cross-sectional study design to
observe the severity and probability of adverse events that
are associated with the use of pregabalin among hemodialysis
(HD) patients suffering from UP.2. Methodology
This was cross-sectional study done among the hemodialysis
patients suffering from UP and receiving HD at Aljaber Kid-
ney Center (AJKC), Al-Ahsa, Eastern Province, Saudi Arabia.
AJKC is the only public dialysis center in Al-Ahsa offering
medical services to patients with ESRD. It is operated under
the directorate of Health Services, Ministry of Health, Saudi
Arabia. ‘‘Al-Ahsa’’ is the Arabic word for ‘‘oasis,’’ and Al-
Ahsa is perhaps the largest oasis in Saudi Arabia. It is known
to be the oldest trade route for merchants in the Gulf region
and is the only oil-producing province in Saudi Arabia. The
majority of the population resides in three main areas: Al-
Hufuf, Al-Dammam and Al-Mubarraz. Nearly 70–80% of
Al-Ahsa residents are Saudi natives, followed by expatriates
from different parts of world. The remaining population is
scattered throughout approximately 50 small villages
surrounding Al-Hufuf, Al-Dammam and Al-Mubarraz
(Al-Hasa, 2013).2.1. Study population
A total of 314 patients are registered for dialysis at AJKC.
These patients are managed in three shifts: morning, afternoon
and evening. Of the total number, 173 are male patients and
112 are female patients. Of whom N= 285 patients are on
HD while the rest are on peritoneal dialysis. On average, about
130 patients are dialyzed on daily basis. Patients visiting for
dialysis during the morning shift were assessed for their poten-
tial enrollment in this study. The assessment of severity and
intensity of UP was done using a validated version of 5D-itch-
ing scale (Khan et al., 2013). The ﬁrst line treatment at AJKC
for UP is loratadine 10 mg daily for two month alone or in
combination with Vaseline lotion as an emollient. If the UP
persists, then the consultant can recommend pregabalin
75 mg to manage the severity of UP. Furthermore, to ensure
the patient safety in advance, a safety assessment protocol
was developed to rule out the patients that should not be pre-
scribed pregabalin or monitored closed due to a higher risk of
adverse events (AEs) (Khan et al., 2014). Upon screening of
the records N= 51 patients were found taking pregabalin
75 mg post hemodialysis (pHD) throughout the study duration
[April 1, 2012, through May 28, 2013].
2.2. Interpretation and analysis of AEs
In order to make the interpretation of AEs more effective and
in line with the evidence-based literature, Naranjo’s algorithm,
known to be a valid measure for reporting and authenticating
drug-related events, was applied (Kathleen et al., 2003;
Naranjo et al., 1981). Naranjo’s algorithm is a ten-item scale
with three options (‘‘yes,’’ ‘‘no,’’ and ‘‘don’t know’’) to express
the occurrence of a drug-related incident. Based on these three
options, a score is assigned for each item. If the total score is of
more than 9, it reﬂects that the AEs are due to the drug being
used by the patient. A probable drug-related AE is assumed if
the score is between 5 and 8, and a possible drug-related AE is
assumed when the score is between 1 and 4. If the score is 0, it
indicates that the AE is not due to the drug in use, but other
factors. Details about the items and scoring pattern for the
Naranjo’s algorithm are shown Table 2. All the patients com-
pleting 42 days of pregabalin therapy were questioned about
any AEs that they may have experienced after taking pregab-
alin. The information was collected based on the patients expe-
rience and the list of the AEs mentioned in Table 2 (Lyrica,
2013). Naranjo’s algorithm was used to estimate the possibility
of an association between these events and pregabalin use.
2.3. Data analysis for the interpretation of adverse events
Possible AEs were listed on a separate data collection form
and were documented based on patient responses. Physician
and nursing staff support were used to interpret patients’ expe-
riences in order to assess the incidence of any of the AEs.
Descriptive statistics were applied to calculate scores based
on Naranjo’s algorithm. A standard scoring pattern was
adopted to quantify the possible association between the
AEs and pregabalin use (Kathleen et al., 2003; Naranjo
et al., 1981). Total scores range from 4 to +13; if the score
is 9 or more than the AE is considered as deﬁnite, probable
if 5–8, possible if 1–4, and doubtful if 0 or less (Kathleen
616 T.M. Khan et al.et al., 2003; Naranjo et al., 1981). Furthermore, a predictive
model was developed using binary multiple logistic regression
to explore association of patients’ demographics and risk fac-
tors with the occurrence of AEs. Overall, six predictive models
were built for six AEs, respectively. Throughout statistical sig-
niﬁcance level was considered signiﬁcant at 0.05.
2.4. Ethics approval
The study protocol was approved by institutional authorities:
the college of clinical pharmacy, deanship of scientiﬁc research
and Al-Jaber Kidney Dialysis Center (AJKDC)/King Fahad
hospital in Al-Ahsa, Saudi Arabia.
3. Results
Upon initial safety screening, ﬁfty one patients were found to
be the potential candidates for the pregabalin therapy. Overall,
most of the patients that were selected after safety assessment
were from the age group 40–70 years [Mean = 55.54 yrs ± SD
13.29, Median = 55 yrs]. Majority of the patients 36 (70.6%)
were male, and 48 (94.1%) were married. In terms of education
level most of them having primary education, followed by high
school/college and Islamic education. While investigating the
occupational status it was revealed that 20 (39.2%) of the
patients were government employees and about 17 (33.3%)
were jobless (Table 1).
3.1. Assessment for AEs
The assessment for the safety of pregabalin was done using the
manufacturer guide for the patients who have taken pregabalinTable 1 Demographic information of patients.
Demographic variables N (%)
Gender
Male 36(70.6%)
Female 15(29.4%)
Education
Primary 17(33.3%)
Secondary 7(13.7%)
College/high school 15(29.4%)
Islamic education 12(23.5%)
Job status
Jobless 17(33.3%)
House wife/stay at home 7(13.7%)
Own business 1(2.0%)
Private company job 3(5.9%)
Government job 20(39.2%)
Farm/agriculture job/business 3(5.9%)
Marital status
Married 48(94.1%)
Single 1(2.0%)
Divorced 1(2.0%)
Widowed 1(2.0%)
Smoking habit
Active smokers 19(37.3%)
Non-smokers 32(62.7%)for the duration of 6 weeks or more. Overall, Dizziness was
reported by 47.0% of the patients followed by somnolence
22 (43.1%), constipation 15 (29.4%), blurred vision 10
(19.6%), weight gain 6 (11.8%) and edema 5 (9.8%) dry mouth
3 (5.9%). However, in some cases it was difﬁcult to rule out the
associate of an event with the pregabalin use, because some of
the patients they reported that they were facing such complica-
tion from last two months or more (e.g. dry mouth, edema and
headaches). Moreover in some case for example weight gain, it
was hard to conclude that either the variations are due to pre-
gabalin or due to the ESRD. Therefore weight gain was only
associated with pregabalin in the case when the increase is
more than 5.0 kg in comparison with their baseline assessment.
In the case where is a risk of doubt, such incidence was ranked
as undecided (Table 2).
For the conﬁrmed AEs Naranjo’s algorithm was applied to
estimate the possibility of an association of the event with pre-
gabalin use. Upon calculation of the score it was revealed that
weight gain and edema (score = 4) have a possible association
with the administration of pregabalin. While somnolence,
blurred vision, dysarthria, and constipation were found to
have probable association with the administration of pregaba-
lin (score = 4). Details are shown in Table 3.
Furthermore, to assess the possible association among AEs
with the age, gender and comorbidities were assessed using
binary multiple logistic regression model. Overall, no statisti-
cally signiﬁcant association was observed. However, it was
noticed that female patients aged less than 50 years were found
to be at a higher risk in comparison with men. Moreover, those
patients having one comorbid complication (i.e. hypertension
or diabetes mellitus alone) were at a higher risk of somnolence,
weight gain and dry mouth. Details are shown in Table 4.
4. Discussion
Assessment of the AEs is one of the important aspects of drug
safety, which is always preferred by the clinician before
approving a drug for the patient with lifelong disease condi-
tions or with compromised organ functions. Recent studies
exploring the safety of pregabalin reported a variety of AEs
among the patients (Zaccara et al., 2011). Perucca et al.
(2009) stated that the AEs of pregabalin may reduce the qual-
ity of life of patients (Perucca et al., 2009). Overall, the com-
mon AEs reported were associated with ‘‘cognition/Table 2 Assessment for conﬁrm AEs.
Adverse events (AEs) Conﬁrm N (%) Un decided N (%)
Somnolence 22(43.1%) –
Dizziness 24(47.0%) –
Dry mouth 3(5.9%) 3(5.9%)
Blurred vision 10(19.6%) –
Memory disturbances – –
Constipation 15(29.4%) –
Dysarthria – –
Weight gain 6(11.8%) 8(15.7%)
Edema 5(9.8%) 4(7.84%)
Impotence – –
Headache – 7(13.7%)
Flu syndrome – –
Gynecomastia – –
Table 3 Assessment of itching distribution on day forty two.
AEs Conﬁrm N (%) Score based on Naranjo’s algorithm AEs assessment based on Naranjo’s algorithm
Somnolence 22(43.1%) 7 Probable
Dizziness 24(47.0%) 7 Probable
Blurred vision 10(19.6%) 7 Probable
Dry mouth 3(5.9%) 7 Probable
Constipation 15(29.4%) 7 Probable
Weight gain 6(11.8%) 4 Possible
Edema 5(9.8%) 4 Possible
Table 4 Variables associated with the AEs.
Adverse event Variables OR (CI-95%) p-Value
Somnolence Age (<50 years) 0.981[0.941–1.022] 0.349
Gender (female) 1.656[0.476–5.766] 0.428
Comorbidities (1 CM) 1.340[0.394–4.561] 0.639
Vision disturbances Age (<50 years) 1.025[0.283–3.710] 0.969
Gender (female) 1.014[0.974–1.056] 0.496
Dry mouth Age (<50 years) 0.971[0.908–1.037] 0.381
Gender (female) 0.842[0.134–5.297] 0.855
Comorbidities (1 CM) 6.107[0.587–9.592] 0.130
Constipation Age (<50 years) 0.956[0.915–0.998] 0.041*
Gender (female) 0.694[0.194–2.485] 0.574
Weight gain Age (<50 years) 0.964[0.900–1.033] 0.298
Gender (female) 0.710[0.110–4.574] 0.718
Comorbidities (1 CM) 1.907[0.266–13.669] 0.521
Edema Age (<50 years) 0.974[0.908–1.045] 0.458
Gender (female) 1.207[0.162–8.974] 0.854
Variable(s) entered on step 1: Age, gender and Comorbidities.
CM= Comorbidity.
* p-Value < 0.05
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the patients (Liao et al., 2008; Nakagawasai et al., 2010;
Perucca et al., 2009; Zhuchenko et al., 1997). Common AEs
that were observed among the pregabalin users were dizziness,
vertigo, incoordination, balance disorder, ataxia, tremor, dip-
lopia, blurred vision, euphoria, poor or lack of attention,
abnormal thinking, somnolence, confusion, asthenia, fatigue
and amblyopia. Ben-Menachem (2004) associated the inhibi-
tion of depolarization-dependent inﬂux as the main reason
for the decreased neurotransmitter release (Porter et al.,
2004; Ben-Menachem, 2004). Therefore, alterations in the nor-
mal levels of neurotransmitters in the central nervous system
will lead to these AEs, which increase in severity with increased
dose (Liao et al., 2008; Porter et al., 2004; Zhuchenko et al.,
1997). Moreover, the other AEs, including edema, peripheral
edema, dry mouth and constipation, were not found to be
associated with increased dose (Zaccara et al., 2011).
However, the study population of the current study was dif-
ferent from the samples of previous studies addressing safety
of pregabalin (Liao et al., 2008; Nakagawasai et al., 2010;
Perucca et al., 2009; Porter et al., 2004; Zhuchenko et al.,
1997). Therefore, the likelihood of the AEs that were dose
dependent was less. Randinitis et al. (2003) have shown phar-
macokinetic justiﬁcations that limit the dose of pregabalin to
75 mg per day for patients with compromised renal function
(Randinitis et al., 2003). Most of the recent case reports andcross-sectional studies that have studied the effect of pregaba-
lin in refractory pruritus among ESRD patients have used a
dose of 25–75 mg per day and, in most cases, the effect and
safety of pregabalin were observed after 4 weeks (Aperis
et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012;
Shavit et al., 2013; Solak et al., 2012). Among ESRD patients,
the common AEs observed were dizziness, somnolence and
over-sedation. Similar to the ﬁndings of Aperis et al. (2010),
Rayner et al. (2012) and Solak et al. (2012), somnolence and
dizziness were the frequent adverse event presented by the
majority of the patients. Moreover, other AEs were constipa-
tion (29.4%), weight gain (11.8%) and edema (9.8%). How-
ever, in some cases, some of the AEs were hard to rule out,
and were therefore considered ‘‘undecided’’. Certain complica-
tions, including weight gain and edema, are also associated
with the ESRD itself, and the patients’ medical records show
frequent variations in the weight and ﬂuid accumulation
among the patients (Chamney et al., 2002). Therefore, in the
case where patients had frequent variation in weight and ﬂuid
accumulation, the beneﬁt of the doubt was given to pregabalin
and the incidence of such events was marked as undecided.
However, the probability of AEs was not conﬁrmed through
the Naranjo algorithm for weight gain (score = 4) and edema
(score = 4). Somnolence, dizziness, blurred vision, dysarthria
and constipation were found to be probable AEs due to pre-
gabalin use.
618 T.M. Khan et al.In the current sample, it is hard to associate the genetic ele-
ment with the incidence of AEs observed after pregabalin use.
Two main challenges hinder a valid conclusion in this regard:
one is the lack of a safety proﬁle of pregabalin among Arabs,
and the second is the deﬁcient pharmacokinetic proﬁle among
patients with ESRD. Therefore, it is possible that the genetic
composition of the current sample is one of the factors that
may have augmented the chance of AEs, such as somnolence
and dizziness, in the current sample, and perhaps due to this
reason, the incidence of these events was double when com-
pared to other studies that investigated the use of pregabalin
among UP patients (Aperis et al., 2010; Ehrchen and
Stander, 2008; Rayner et al., 2012; Shavit et al., 2013; Solak
et al., 2012). Moreover, other AEs including constipation
(29.4%), weight gain (11.8%) and edema (9.8%) were only
observed in the current sample, and it can be assumed that
genetic factors might be one of the inﬂuencing factors that pro-
voke the AEs that were not observed by other studies (Aperis
et al., 2010; Ehrchen and Stander, 2008; Rayner et al., 2012;
Shavit et al., 2013; Solak et al., 2012). Along with the genetic
issues, ESRD itself can be one of the reasons for the events
such as dizziness, headaches, dry mouth, somatic symptoms
and somnolence (Brown and Gower, 1982; NHS, 2013). How-
ever, keeping in mind the scarcity of evidence in this regard,
the ability of the current study to draw a solid conclusion
about the association of genetics with the AEs observed is lim-
ited. Future research among ESRD patients and non-ESRD
patients will be helpful in providing evidence to determine
the association of genetics with the AEs observed with pregab-
alin use.
Particularly addressing the gastrointestinal (GIT) complica-
tions associated with the use of pregabalin, it was noted that
about 17 (33.4%) patients were taking lactulose before starting
pregabalin therapy. In other words, it can be stated that 33.4%
of the patients had GIT symptoms, i.e. constipation before
using the pregabalin, which is a common complication faced
by most of the ESRD patients that are on HD
(Singharetnam and Holley, 1996; Wu et al., 2004; Yasuda
et al., 2002). Most of HD patients are on oral iron supplemen-
tation. Oral iron consumption is reported to be a known rea-
son for the GIT complications, such as constipation, among
normal patients and those with ESRD (Suh and Wadhwa,
1992; Van Wyck et al., 2005). Thus concurrent use of iron with
ESRD itself has a major role in resulting GIT complications,
including constipation. However, based on the Naranjo algo-
rithm, it seems that constipation is associated with the use of
pregabalin. Though, in the presence of confounders, including
prior episodes of constipation before starting pregabalin and
concurrent use of iron during ESRD, it might be clinically dif-
ﬁcult to prove a signiﬁcant associate of constipation with the
pregabalin administration.
By exploring the association of other AEs with the demo-
graphics and comorbidities using a multiple logistic regression
model, it was revealed that visual disturbances were more com-
mon among the male patients with odds ratio of 1.014 [95%
CI: 0.974–1.056] compared to female ones. Moreover, about
24 (47.1%) of the patients had diabetes mellitus, which is a
known cause of visual complications among the patients
(Lee et al., 1997; Nakamura et al., 2005). In addition, the
majority of the patients in the current sample were aged more
than 50 years, which is in line with the increased risk with odds
ratio of 1.025 [95% CI: 0.283–3.710] in our predictive modelfor the visual complications among the current sample. Fur-
thermore, it is possible that administration of pregabalin might
have worsened the visual acuity of the patients. However, it is
noteworthy that although the statistical signiﬁcance was not
observed in the current predictive model, our regression-based
approach is useful to control for all potential risk factors to
obtain better precision.
5. Conclusion
Naranjo’s quantiﬁcation for the possibility and probability of
AEs is a beneﬁcial measure to rule out the possibility and
probability of AEs. AEs observed in this study were moderate
in nature and well tolerated by the patients. Age, gender and
comorbid medical conditions are some of the factors that
might have clinical association with the occurrence of the AEs.
6. Clinical implications
Overall, the ﬁndings of the current study reﬂect that pregabalin
is safe for use among ESRD patients. That is why there were
no dropouts, unlike other studies that have used pregabalin
to treat UP (Aperis et al., 2010; Ehrchen and Stander, 2008;
Rayner et al., 2012; Shavit et al., 2013; Solak et al., 2012).
Moreover, an initial safety assessment before starting pregab-
alin can be an effective measure to monitor the patients that
might be at a higher risk of AEs (Khan et al., 2014). Thus,
in cases where pregabalin is contraindicated or may complicate
the patient’s situation, such cases should be identiﬁed in
advance and monitored closely or considered for alternative
treatment options.7. Limitations of study
The current study was an observational study addressing the
safety of Pregabalin among patients with treatment resistant
pruritus. Due to the ethical and regulatory reason, it was not
possible to allocate a control group for the effective
comparison.
8. Recommendations for future research
The time duration of current study was small, assessment for
safety was done on day 42 and there was no longitudinal data
available to estimate the long term effect of drug. Future stud-
ies planning to address the same issue should consider adopt-
ing a longitudinal study design to estimate the safety proﬁle of
pregabalin in long run.
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